PubRank

Harry D Bear

Author PubWeight™ 55.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008 6.31
2 Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012 4.33
3 Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol 2013 2.59
4 Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005 2.17
5 Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 2009 2.14
6 A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011 1.99
7 GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res Treat 2009 1.60
8 Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008 1.42
9 Breast conservation therapy rates are no different in medically indigent versus insured patients with early stage breast cancer. J Surg Oncol 2003 1.39
10 Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 2008 1.38
11 Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother 2008 1.30
12 Human T cells express CD25 and Foxp3 upon activation and exhibit effector/memory phenotypes without any regulatory/suppressor function. J Transl Med 2009 1.26
13 Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 2013 1.16
14 Cutting edge: mast cells critically augment myeloid-derived suppressor cell activity. J Immunol 2012 1.15
15 Effects of surgical excision on survival of patients with stage IV breast cancer. J Surg Res 2009 1.10
16 Partial breast brachytherapy after lumpectomy: low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys 2003 1.05
17 Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse. J Immunol 2011 1.04
18 IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo. Breast Cancer Res Treat 2009 1.03
19 Insurance and inpatient care: differences in length of stay and costs between surgically treated cancer patients. Cancer 2012 1.03
20 Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013 1.03
21 Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat 2008 0.98
22 Successful adoptive immunotherapy with vaccine-sensitized T cells, despite no effect with vaccination alone in a weakly immunogenic tumor model. Cancer Immunol Immunother 2003 0.97
23 A gene transcription signature of obesity in breast cancer. Breast Cancer Res Treat 2011 0.96
24 Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells. Breast Cancer Res Treat 2013 0.92
25 Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007 0.92
26 Bevacizumab and breast cancer: what does the future hold? Future Oncol 2012 0.92
27 Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes. Int Immunol 2004 0.89
28 Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions. Surg Clin North Am 2003 0.88
29 Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010 0.88
30 Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 2011 0.87
31 Methyl-binding domain protein 2-dependent proliferation and survival of breast cancer cells. Mol Cancer Res 2011 0.87
32 Myeloid-derived suppressor cells enhance IgE-mediated mast cell responses. J Leukoc Biol 2013 0.86
33 Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma. BMC Immunol 2010 0.85
34 Ex vivo expansion of tumor-reactive T cells by means of bryostatin 1/ionomycin and the common gamma chain cytokines formulation. J Vis Exp 2011 0.81
35 Tumor bed boost omission after negative re-excision in breast-conservation treatment. Ann Surg Oncol 2006 0.79
36 Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT. J Nucl Med 2011 0.79
37 Taking action on the volume-quality relationship: how long can we hide our heads in the colostomy bag? J Natl Cancer Inst 2003 0.78
38 Intraoperative injection of radiocolloid for sentinel node biopsy in breast cancer. J Nucl Med Technol 2013 0.78
39 Measuring circulating tumor cells as a surrogate end point for adjuvant therapy of breast cancer: what do they mean and what should we do about them? J Clin Oncol 2008 0.78
40 Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity. Ann Surg Oncol 2002 0.76
41 Earlier chemotherapy for breast cancer: perhaps too late but still useful. Ann Surg Oncol 2003 0.76
42 The role of margin status and reexcision in local recurrence following breast conservation surgery. Ann Surg Oncol 2013 0.76
43 Completion axillary lymph node dissection for breast cancer: immediate versus delayed versus none. J Clin Oncol 2008 0.75
44 Sentinel node micrometastases and non-sentinel nodes in breast cancer: how much do we need to know? J Clin Oncol 2006 0.75
45 Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol 2014 0.75
46 The impact of physician and hospital volume on the quality of surgical outcomes. J Surg Oncol 2003 0.75
47 Reaping the harvest from neoadjuvant therapy for breast cancer: reducing morbidity with sentinel lymph node biopsy. J Surg Oncol 2007 0.75